Skip to main content
Premium Trial:

Request an Annual Quote

Ed Umali, David Haen, Carolyn French


A week after naming a full-time CFO, CytRx said that it has expanded its management team by three people, all of whom come from CEO Steve Kriegsman’s investment firm, The Kriegsman Group.

CytRx said that it has tapped Ed Umali as director of operations, David Haen as director of business operations, and Carolyn French as director of communications.

French’s position at CytRx is on a full-time basis, while Umali and Haen are expected to continue to provide certain services to The Kriegsman Group on a limited basis.

Following its 2002 merger with Global Genomics, CytRx was stripped down by Kriegsman and set on a new course: to develop therapeutics based on RNAi. Part of that overhaul included building a new management team, a task Kriegsman said has now completed.

“All of the slots have been filled,” he said. “We’ve got a team in place to do whatever we need to do.”

CytRx now has nine employees, he said. This does not include the roughly 10 UMass researchers conducting work for the company under a sponsored research agreement.


The Scan

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in in human genomic research, and more.

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.